Headlines about Alexion Pharmaceuticals (NASDAQ:ALXN) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alexion Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.823033980666 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news stories that may have effected Accern’s analysis:
- Alexion to Report Fourth Quarter and Full Year 2017 Results on Thursday, February 8, 2018 (finance.yahoo.com)
- Credit Suisse Group Reaffirms “Buy” Rating for Alexion Pharmaceuticals (ALXN) (americanbankingnews.com)
- Alexion Pharmaceuticals, Inc. (ALXN) Nice-Looking Insider Ownership of 0.10% – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Short Term Technical Analysis: Alexion Pharmaceuticals, Inc. (ALXN), Ciena Corporation (CIEN) – Market Movers (financialqz.com)
- Analysts Expect Alexion Pharmaceuticals, Inc. (ALXN) Will Post Earnings of $1.28 Per Share (americanbankingnews.com)
Shares of Alexion Pharmaceuticals (NASDAQ ALXN) traded down $1.77 during trading hours on Thursday, reaching $120.35. The company’s stock had a trading volume of 1,480,000 shares, compared to its average volume of 2,140,000. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35. Alexion Pharmaceuticals has a fifty-two week low of $96.18 and a fifty-two week high of $149.34. The company has a market cap of $26,890.00, a PE ratio of 53.73, a PEG ratio of 1.04 and a beta of 1.17.
A number of equities analysts recently issued reports on the company. Leerink Swann reiterated a “buy” rating and issued a $182.00 target price on shares of Alexion Pharmaceuticals in a report on Monday, September 25th. Zacks Investment Research cut Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Piper Jaffray Companies reiterated an “overweight” rating and issued a $170.00 target price on shares of Alexion Pharmaceuticals in a report on Monday, October 23rd. Royal Bank of Canada increased their target price on Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. Finally, Stifel Nicolaus cut their target price on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a report on Tuesday, October 24th. One research analyst has rated the stock with a sell rating, three have given a hold rating and nineteen have given a buy rating to the stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $153.10.
In other news, CEO Ludwig Hantson sold 2,553 shares of Alexion Pharmaceuticals stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total transaction of $310,521.39. Following the sale, the chief executive officer now directly owns 36,172 shares in the company, valued at approximately $4,399,600.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.35% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Alexion Pharmaceuticals (ALXN) Stock Price” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3144787/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-alexion-pharmaceuticals-alxn-stock-price.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.